Ticker brief
RARE
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
11
authors 14d
8
crowd 14d
+0.7σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-14 · now +0.35 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -1.06 | 3 | +0.42 |
| @PrismMarketView | C | · | 2 | +0.08 |
| @BaldwinDunas | · | -0.54 | 1 | +0.15 |
| @aljehani | C | -1.16 | 1 | +0.35 |
| @fwpharma | B | -1.91 | 1 | +0.20 |
| @AIStockSavvy | C | -1.05 | 1 | +0.30 |
| @SeegerErik | C | -1.23 | 1 | +0.00 |
| @BioStocks | C | -1.77 | 1 | +0.35 |
Recent signals11of 11 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-14 | @semodough | +0.35 | Reports RARE sold two priority-review vouchers, raising $413M cash within seven days. | · | tweet ↗ |
| 2026-10-14 | @BioStocks | +0.35 | Reports RARE sold a priority-review voucher for $203 million. | · | tweet ↗ |
| 2026-10-12 | @PrismMarketView | -0.15 | Summarizes a Phase 3 miss, FDA-path efforts, an approval and another developer's oral program. | · | tweet ↗ |
| 2026-10-11 | @semodough | +0.65 | Cantor says new setrusumab analyses suggest clear benefits versus placebo and standard care. | · | tweet ↗ |
| 2026-10-09 | @PrismMarketView | +0.30 | RARE agreed to sell a priority review voucher for $210 million. | · | tweet ↗ |
| 2026-10-09 | @SeegerErik | +0.00 | Reports QSI's 19-amino-acid Proteus milestone and price gain; peers appear only in an analyst headline | · | tweet ↗ |
| 2026-10-08 | @AIStockSavvy | +0.30 | H.C. Wainwright reiterated Buy and a $25 target on Ultragenyx. | · | tweet ↗ |
| 2026-10-08 | @fwpharma | +0.20 | Ultragenyx sold a priority-review voucher for $210 million. | · | tweet ↗ |
| 2026-10-07 | @semodough | +0.25 | Notes biotech priority-review vouchers are now transacting for more than $200 million. | · | tweet ↗ |
| 2026-10-07 | @aljehani | +0.35 | Ultragenyx agreed to sell a rare-pediatric-disease priority-review voucher for $210M. | · | tweet ↗ |
| 2026-10-05 | @BaldwinDunas | +0.15 | Rebuy RESOLV here with a 20% stop for a 30-60 day hold. — Calls for a RESOLV rebuy with stop, horizon and rotation thesis. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.